Our Biosimilars

REAL-WORLD EVIDENCE THAT CAN'T BE REPLICATED

With 5 approved biosimilars, and more in development, we're fully committed to the long-term success of biosimilars.

Innovator Oncology Portfolio

10

products, including therapeutic and supportive care

Supply

0 shortages,
including biosimilars, for more than a decade* through natural disasters and during
COVID-19

Favorable Coverage

>87%

of lives covered—unrestricted, with no step edit required for KANJINTI® and MVASI®†

Patients Treated

>205K

with Amgen Biosimilars

Global Network

100

countries in the manufacturing and distribution network

Patients Supported

4200+

by Amgen Assist 360™ for MVASI® and KANJINTI®§

EXPLORE OUR VIDEOS ON BIOSIMILARS

My Experience With Biosimilars

Watch Lee Schwartzber, MD, FACP, and Chris Marcum, PharmD, share their experiences with biosimilars.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Supply Shortages in Oncology

      Watch Chris Marcum, PharmD, talk about why reliable drug supply is critical in oncology.

      Video Player is loading.
      Current Time 0:00
      Duration 0:00
      Loaded: 0%
      Stream Type LIVE
      Remaining Time 0:00
       
      1x
        • Chapters
        • descriptions off, selected
        • captions off, selected

          QUALITY FAST FACTS

          Watch a high-level overview of ensuring the quality of biosimilars.

          Video Player is loading.
          Current Time 0:00
          Duration 0:00
          Loaded: 0%
          Stream Type LIVE
          Remaining Time 0:00
           
          1x
            • Chapters
            • descriptions off, selected
            • captions off, selected

              EFFICACY FAST FACTS

              Watch an overview of efficacy as it relates to biosimilars.

              Video Player is loading.
              Current Time 0:00
              Duration 0:00
              Loaded: 0%
              Stream Type LIVE
              Remaining Time 0:00
               
              1x
                • Chapters
                • descriptions off, selected
                • captions off, selected

                  *From American Society of Health System Pharmacists: ongoing data monitoring (2007-2017) (2019-2021); FDA (2018-2020).
                  From MMIT coverage in February 2021 for KANJINTI® and MVASI®. Covered is defined as covered with no step edit. The data represent plan participants enrolled in commercial and Medicare Advantage plans.
                  Based on global data, and includes an inflammation biosimilar.
                  §As of March 2021.